the upside, page-7

wg159

See my response to Kalala on deals status, and earlier responses on the same topic in different threads. The developments are exciting and far from failures.

You need to stop generalising about what other companies are doing. Stem cells are not alike. MSB's patented MPCs are unique, and that's why we have over 600 patents protecting the multiplicity of applications.

If you understand the science, you will understand that earlier FDA stages have demonstrated efficacy, even though technically MSB didn't have to prove it. Indeed, we went further and established optimal dosages in clinical trials that were more about safety.

The FDA has endorsed an approach of reducing stage 3 at the halfway point, if efficacy is proven (which there is no reason to assume it will not, you need to understand the science to get this). MSB is acknowledged as world leader in stem cell research and development. There is a reason for this.

Further, as the CEO pointed out at the AGM, and has been reported in here, the size and scope of FDA trials have been about using a pharmaceutical model, which only deals with certain streams of manifestation of the illness which is lower down the line. MPCs are high up the line and therefore the possibility of patient rejection and complications resulting from DNA response are (implicitly) negligible.

There are multiple unknowns with patient responses and the pharmaceutical drug testing, hence the huge cost and scope of stage 3 clinical trials. The willingness of the Japanese to fast track clinical trials on the aGVHD application, followed by the FDA shows the way of the future.

This is unlike other products. Do not apply inappropriate models to this. It won't work.

(PS I'm sure the shorters are really quite worried... what will be the new trading price?).